According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

I normally do not write letters to the editor regarding matters of appeals of criminal convictions but this one is especially egregious. Everyone knows about the case brought against the woman ...

Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

writing hundreds of letters in which she used racist slurs and falsely alleged that a care worker was abusing patients, has failed to convince the Court of Appeal that her two-year jail term was ...

NEW YORK -- The NHL Players' Association said Wednesday it has filed an appeal on Ryan Hartman's behalf after the Minnesota Wild forward was suspended 10 games for roughing. Hartman had 48 hours ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...

Libyan authorities found nearly 50 bodies in two mass graves in the country’s southeastern desert Monday, demonstrating the persistent dangers faced by migrants seeking passage to Europe through the ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...